

**Table 13. Budget impact for four months panitumumab as fourth line treatment**

	30 patients	50 patients
Comparator: regorafenib		
Panitumumab total medicines acquisition cost*	¶¶¶	¶¶¶
Regorafenib (Stivaga®) 2 months <sup>†§</sup> + 2 months BSC <sup>¶</sup> total medicines acquisition cost	¶¶¶	¶¶¶
<b>Overall net cost</b>	¶¶¶	¶¶¶
<p>Costs exclude VAT</p> <p>Average adult weight 79 kg<sup>30</sup></p> <p>Mean body surface area 1.79 m<sup>240</sup></p> <p>*6 mg/kg IV infusion every 2 weeks<sup>1</sup></p> <p>†160 mg daily for 3 weeks, 1 week off<sup>37</sup></p> <p>§Mean of median treatment durations in CORRECT (1.7 months) and CONCUR (2.4 months)<sup>28,29</sup></p> <p>¶Two months of comparator medicine costs only, no medicine acquisition costs are provided for BSC</p> <p>BSC: best supportive care</p> <p>¶¶¶ commercial in confidence figure removed</p>		